This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a contemporaneous Day 1-6 supportive care control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 160 participants
Primary Purpose: Treatment
Actual Study Start Date: April 1, 2020
Estimated Study Completion Date: April 30, 2021
* Additional criteria apply. Please speak with the study team for further information.
Experimental: Arm 1: Hydroxychloroquine Sulfate + Azithromycin
Experimental: Arm 2: Hydroxychloroquine Sulfate alone
No Intervention: Arm 3: Supportive Care
Thank you for your interest in advancing COVID-19 research.
To learn more about this study, please fill out the interest form to be connected to a member of the study team. The following contact information that you enter into this form will only be shared with the research team conducting this specific study.
If you have any difficulties or questions, please contact our support specialists at [email protected]
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.